Searchable abstracts of presentations at key conferences in endocrinology

ea0049gp99 | Diabetes therapy & complications 1 | ECE2017

Higher levels of adiponectin might contribute to lower bone mass observed in patients with type 1 diabetes, through alterations in osteocalcin energy circuit signaling of bone cells.

Tsentidis Charalampos , Gourgiotis Dimitrios , Kossiva Lydia , Doulgeraki Artemis , Marmarinos Antonios , Karavanaki Kyriaki

Introduction: Recent advances in energy homeostasis revealed a significant interconnection between bone and adipose tissue through osteocalcin. Reduced bone mass documented in type 1 diabetes mellitus (T1D) could be related to disregulation of adipokine signaling on bone.Materials and Methods: We evaluated 40 children and adolescents with T1D (mean±S.D. age 13.04±3.53 years, mean±S.D. T1D duration 5.15±3....

ea0037gp.12.06 | Diabetes and obesity – Translational diabetes | ECE2015

Increased levels of Dickkopf-1 may indicate lower osteoblast signaling, predisposing to lower bone mineral density in children and adolescents with type 1 diabetes mellitus

Tsentidis Charalampos , Gourgiotis Dimitrios , Kossiva Lydia , Marmarinos Antonios , Doulgeraki Artemis , Karavanaki Kyriaki

Introduction: T1DM is a risk factor for reduced bone mass, disrupting several bone metabolic pathways. Dickkopf-1 is an inhibitor of the Wnt/b-catenin bone metabolic pathway. Increased fracture risk and elevated Dickkopf-1 levels have been documented in adult patients with T2DM. No relevant data exist on childhood T1DM. Our aim was to study plasma Dickkopf-1 concentration in children and adolescents with T1DM and controls and to correlate Dickkopf-1 levels with metabolic bone ...

ea0035p427 | Diabetes complications | ECE2014

Sclerostin distribution in children and adolescents with type 1 diabetes mellitus and correlation with bone metabolism markers and bone mineral density

Tsentidis Charalampos , Gourgiotis Dimitrios , Kossiva Lydia , Marmarinos Antonios , Doulgeraki Artemis , Karavanaki Kyriaki

Introduction: Sclerostin is an inhibitor of the Wnt/β-catenin bone metabolic pathway. Increased sclerostin levels and reduced bone mineral density (BMD) have been documented in adult patients with diabetes mellitus (DM), predominantly in those with type 2 diabetes mellitus (T2DM). No relevant data exist on childhood T1DM. Our aim was to study plasma sclerostin concentration in children and adolescents with T1DM and controls and to correlate sclerostin levels with metaboli...

ea0035p428 | Diabetes complications | ECE2014

Higher levels of osteoprotegerin and S-RANKL in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast activity and predisposition to lower bone mass

Tsentidis Charalampos , Gourgiotis Dimitrios , Kossiva Lydia , Doulgeraki Artemis , Marmarinos Antonios , Karavanaki Kyriaki

Introduction: Diabetes mellitus (DM) is a risk factor for reduced bone mass. Several bone metabolic pathways seem to be disrupted in patients with type 1 diabetes mellitus (T1DM).Materials and methods: We evaluated 40 children and adolescents with T1DM (mean±S.D., age 13.04±3.53 years, mean±S.D., T1DM duration 5.15±3.33 years) and 40 healthy age- and gender-matched controls (mean±S.D.,...

ea0056p249 | Calcium & Vitamin D metabolism | ECE2018

Prenatal hypophosphatasia with severe skull bone deficits report of a case

Sideri Vassiliki , Karachaliou Feneli , Kapsabeli Helen , Doulgeraki Artemis , Dakalaki Anna , Papaevangelou Vassiliki

Hypophosphatasia (HPP) is a rare inherited disorder caused by loss-of-function mutations in the tissue-nonspecific alkaline phosphatase (TNSALP) gene. HPP B is a multisystemic B disorder with a predominantly B skeletal phenotype, with a clinical spectrum ranging from high lethality in early onset (<6 months) HPP to mild late-onset presentations. HPP skeletal disease in utero was thought to predict a lethal outcome. However a benign prenatal form (PB HPP) with a mild postna...

ea0070aep125 | Bone and Calcium | ECE2020

Impaired bone health at cancer diagnosis in paediatric patients

Nikita Maria , Doulgeraki Artemis , Kanaka-Gantenbein Christina , Karavanaki Kyriaki , Servitzogloy Marina , Athanasopoulou Helen , Polyzois George , Tsentidis Charalampos , Baka Margarita , Kossiva Lydia

Objectives: To evaluate the skeletal profile of paediatric patients with cancer at diagnosis.Methods: Children diagnosed with cancer in our Oncology Centre were recruited during a two-year period and underwent metabolic bone profile and dual-energy X-ray absorptiometry (DXA) at the time of diagnosis.Results: 88 children were evaluated (51 boys, 53 prepubertal), aged 7.6 ± 4.6 years. Of those, 50 were diagnosed with haematologi...